close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Revolution Health Acquires HealthTalk

WASHINGTON & SEATTLE--(BUSINESS WIRE)--Dec 5, 2007 - Revolution Health, a leading health company founded by AOL co-founder Steve Case to transform how people approach their overall health and wellness, today announced the acquisition of HealthTalk, a leading online provider of chronic care information and programming. HealthTalk will operate as part of Revolution Health Network, which encompasses RevolutionHealth.com, CarePages.com and the company's affiliations with drugstore.com and SparkPeople.com.

HealthTalk.com provides in-depth, original multi-media health content to more than 1 million unique visitors per month. Additionally, the company has amassed more than 500,000 members who receive targeted health information that covers all aspects of patient needs - from treatment to quality of life. HealthTalk members are able to participate in forums that allow patients from all over to interact with world-class experts- no matter where they are located.

Revolution Health Network is the definitive online health community for people at all stages of health - from people seeking to improve everyday health and fitness to people managing acute conditions to people receiving care.

"The acquisition of HealthTalk advances our position as the leading health community on the Internet and adds yet another dimension to the Revolution Health Network family of offerings," said Steve Case, chairman and CEO of Revolution Health Group. "HealthTalk brings to Revolution Health Network an array of unique, deep content and interactive programming that covers the most prevalent acute conditions facing Americans today."

HealthTalk's strength with chronic conditions complements Revolution Health's strength in the health and wellness category. The combination enables Revolution Health Networks to broaden its audience and provide health-involved consumers with a robust offering of content and services for every stage of their lives and the lives of their loved ones.

The expanded reach of the Revolution Health Network combined with the depth of HealthTalk's proprietary content also provides pharmaceutical and biotechnology customers with a unique opportunity to target their audiences in a more meaningful way. With the HealthTalk.com acquisition, Revolution Health Network now reaches more than 12 million unique visitors per month, making it the second largest health information destination on the Internet.

The HealthTalk.com acquisition brings with it a veteran management team with extensive experience at many of the industry's leading properties, including WebMD, Discovery, Everyday Health and Oxygen Media.

"We are very excited about becoming part of Revolution Health," said Mike Cunnion, president of HealthTalk. "We are philosophically aligned in our mission to provide the best and most useful health information to consumers and to provide valuable new opportunities to our advertisers."

About Revolution Health

Revolution Health Group LLC was created by AOL Co-Founder Steve Case to create products and services that empower people by putting them at the center of the health system. The cornerstone of the company is RevolutionHealth.com, which was recently named the Best Overall Internet Health Site by the eHealthcare Leadership Awards. The free consumer health and medical web site marries expert content and online tools with the power of social networking. Revolution Health also offers premium services that enable companies to provide health content and customized online tools to their employees, an insurance marketplace and CarePages (www.carepages.com), the leading service that enables communication among family and friends when someone is receiving care. For more information go to http://www.RevolutionHealth.com.

About HealthTalk

HealthTalk is a leading Internet-based health information network for patients and caregivers living with a chronic condition. HealthTalk reaches over 500,000 community members each month. The mission of HealthTalk is to inform and empower the nation's growing chronic care population by providing indispensable, hyper-relevant information and support through active communities, multimedia programming and advice from the nation's leading medical experts. http://www.HealthTalk.com

Contact

Revolution Health
Brad Burns, 202-776-1400
brad.burns@revolution.com

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...